Dutch-based biopharmaceutical company, Prosensa has raised €23m in new equity financing to advance its portfolio of RNA-modulating therapeutics for the treatment of rare diseases, including Duchenne muscular dystrophy (DMD), Myotonic Dystrophy (DM1) and Huntington’s disease (HD). The financing round was led by new investor New Enterprise Associates (NEA) and was supported by existing Prosensa investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital.
Prosensa CEO Hans Schikan said the financing will help them to further strengthen the company’s position in rare diseases and will allow them to accelerate the development of treatments for patients in need.
The company’s DMD compounds are based on its proprietary exon-skipping technology that uses antisense oligonucleotides to restore expression of a functional dystrophin protein and to provide potential treatment for DMD patients.
Prosensa is focused on the discovery, development and commercialization of RNA-modulating therapeutics correcting gene expression in diseases with significant unmet need.
